NCT02974777

The IDEAL-PCI Extended Registry

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Extended Registry

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Kaiser Franz Josef Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer). IDEAL-PCI Extended is the continuation of the IDEAL-PCI registry with additional focus on bleeding events and net clinical benefit

Detailed description

Determination of platelet reactivity in patients with percutaneous coronary Intervention as described in the IDEAL-PCI registry. In the IDEAL-PCI Extended Registry an additional deescalation arm with reduction of the standard dual antiplatelet therapy (DAPT) dosis in case of low platelet reactivity to P2Y12 Inhibition or Aspirin with or without bleeding is implemented.

Conditions

• Coronary Arterioscleroses
• Platelet Dysfunction Due to Drugs

Interventions

Type	Name	Description
DRUG	DAPT reduction	Reduction of standard dose DAPT due to low platelet reactivity
DRUG	DAPT on-target	Standard DAPT within the therapeutic window of platelet reactivity
DRUG	DAPT intensification	Intensification of standard dose DAPT due to high platelet reactivity

Timeline

• Primary completion: 2017-01-01
• Completion: 2017-01-01
• First posted: 2016-11-28
• Last updated: 2018-01-26

Locations

1 site across 1 country: Austria